The Assessment Core has three major goals. The first is to ascertain approximately 150 new participants for the studies being conducted by all of the Subprojects within this next phase of our Program Project. The ascertainment process will include coordinating human participant reviews at the New York State Institute or Basic Research in Developmental Disabilities (IBR), as well as obtaining informed consent for new participants. We will also obtain new informed consents for the approximately 150 participants from our previous studies that will be continuing enrollment in our program, and an additional group of 20 - 30 younger adults with Down syndrome who will be studied in Subproject 3. The second major goal of the Core is to coordinate and conduct comprehensive assessments of our 300 study participants in close collaboration with investigators within Subprojects 1, 2, 3 and 4. Our third goal, in close collaboration with Subproject 1, 2, 3, 4 and the Genetics Core, will be to collect blood samples from program participants for analyses of biomarkers, genotype and epigenetic studies of methylation. The fourth goal will be to enter data from assessments into our Core database to facilitate analyses by Program Subprojects, and to maintain a separate participant tracking database. These activities will ensure that all Program participants are characterized using standardized procedures and common measures, providing rich descriptions of phenotype, facilitating analyses within individual Subprojects, and supporting interactions among Subprojects.
| Schupf, Nicole; Lee, Joseph H; Pang, Deborah et al. (2018) Epidemiology of estrogen and dementia in women with Down syndrome. Free Radic Biol Med 114:62-68 |
| Babulal, Ganesh M; Quiroz, Yakeel T; Albensi, Benedict C et al. (2018) Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimers Dement : |
| Lee, Joseph H; Lee, Annie J; Dang, Lam-Ha et al. (2017) Candidate gene analysis for Alzheimer's disease in adults with Down syndrome. Neurobiol Aging 56:150-158 |
| Esbensen, Anna J; Hooper, Stephen R; Fidler, Deborah et al. (2017) Outcome Measures for Clinical Trials in Down Syndrome. Am J Intellect Dev Disabil 122:247-281 |
| Do, Catherine; Xing, Zhuo; Yu, Y Eugene et al. (2017) Trans-acting epigenetic effects of chromosomal aneuploidies: lessons from Down syndrome and mouse models. Epigenomics 9:189-207 |
| Jenkins, Edmund C; Ye, Lingling; Krinsky-McHale, Sharon J et al. (2016) Telomere longitudinal shortening as a biomarker for dementia status of adults with Down syndrome. Am J Med Genet B Neuropsychiatr Genet 171B:169-74 |
| Mendioroz, Maite; Do, Catherine; Jiang, Xiaoling et al. (2015) Trans effects of chromosome aneuploidies on DNA methylation patterns in human Down syndrome and mouse models. Genome Biol 16:263 |
| Schupf, Nicole; Lee, Annie; Park, Naeun et al. (2015) Candidate genes for Alzheimer's disease are associated with individual differences in plasma levels of beta amyloid peptides in adults with Down syndrome. Neurobiol Aging 36:2907.e1-10 |
| Krinsky-McHale, Sharon J; Silverman, Wayne; Gordon, James et al. (2014) Vision deficits in adults with Down syndrome. J Appl Res Intellect Disabil 27:247-63 |
| Hobbs, Charlotte A; Chowdhury, Shimul; Cleves, Mario A et al. (2014) Genetic epidemiology and nonsyndromic structural birth defects: from candidate genes to epigenetics. JAMA Pediatr 168:371-7 |
Showing the most recent 10 out of 73 publications
